Resultados de la búsqueda 831-840 of 15203 for disordered eating

1. Pérdida de peso Más información - Mayo Clinic

   Hensrud DD, ed. The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy- ...

2. Oncología (médica) - Ensayos clínicos

   The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

3. Using fluorescence angiography to predict and prevent hypoparathyroidism after thyroid surgery - Mayo Clinic

   Using fluorescence angiography to predict and prevent hypoparathyroidism after thyroid surgery. MAC-20471898. Profesionales médicos; Using fluorescence ...

4. Transplant Center de Mayo Clinic - Ensayos clínicos

   The purpose of this study is to compare functional improvement and caregiver burden pre- and post-liver transplant (LT) in four patient and patient's ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

6. Oncología (médica) - Ensayos clínicos

   The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

7. Ensayos clínicos - Neurología

   The purpose of the study is to learn more about inflammatory diseases of the central nervous system (CNS) by collecting patient information, blood sample ...

8. Pérdida de peso - Mayo Clinic

   Hensrud DD, ed. The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Interested in losing weight? Nutrition.gov. https://www.nutrition.gov/topics/healthy- ...

9. Ensayos clínicos - Neurología

   Rochester, Minn. Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies. A Study Of Acute Stimulation For The Modulation Of ...

10. Oncología (médica) - Ensayos clínicos

    The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...